Oppenheimer analyst Steven Lichtman assigned a Buy rating to Integra Lifesciences (IART) today. The company’s shares opened today at $45.71, close to its 52-week low of $42.14.
According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -7.8% and a 45.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Currently, the analyst consensus on Integra Lifesciences is a Moderate Buy with an average price target of $60.73, which is a 32.9% upside from current levels. In a report issued on January 3, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $56 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.50 and a one-year low of $42.14. Currently, Integra Lifesciences has an average volume of 602.7K.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
